New obesity drug combo aims to reduce nausea and vomiting
NCT ID NCT07411560
First seen Feb 20, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This study looks at whether combining two experimental weight-loss drugs (cagrilintide and NNC0480-0389) causes fewer stomach issues like nausea and vomiting compared to taking cagrilintide alone. About 100 women with overweight or obesity will receive both drugs in one period and cagrilintide plus a placebo in another. The trial lasts about 4.5 months and focuses on safety and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel Research Unit
RECRUITINGHarrow, Middlesex, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.